Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood graftsChang, Ying-Jun; Huang, Xiao-JunCurrent Opinion in Hematology: November 2012 - Volume 19 - Issue 6 - p 454–461 doi: 10.1097/MOH.0b013e3283582322 HEMATOPOIETIC STEM CELL TRANSPLANTATION: Edited by Andrea Bacigalupo Abstract Author InformationAuthors Article MetricsMetrics Purpose of review This article summarizes recent improvements and progress with unmanipulated haploidentical blood and marrow transplantation (HBMT) and discusses the difference in outcomes between patients receiving HBMT and those receiving unmanipulated granulocyte colony stimulating factor (G-CSF) mobilized haploidentical peripheral blood (G-PB) grafts as allografts. Recent findings Long-term follow-up confirmed that unmanipulated HBMT is a promising protocol that can be successfully extended to treat severe aplastic anemia. Recent observations regarding immune recovery, infections, and strategy for modified donor lymphocyte infusions have provided insight into the prevention of infections and the decrease in relapse after HBMT. Extensive chronic graft-versus-host disease (GVHD) strongly and negatively impacts patient health-related quality of life, suggesting that it should be successfully controlled. A prospective study suggested the inclusion of HBMT in treatment algorithms as a viable option for adults with acute myeloid leukemia with unfavorable cytogenetics who lack a matched donor. Randomized clinical trials are warranted to investigate whether mixture grafts of G-CSF-mobilized blood and marrow or G-PB alone should be chosen as allografts in haploidentical settings. Summary Unmanipulated HBMT is a reliable protocol. New strategies should be investigated to decrease the incidences of GVHD and relapse. Novel mobilization regimens such as AMD3100 alone or G-CSF+AMD3100 for allograft engineering may improve transplant outcomes following HBMT. Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China Correspondence to Xiao-Jun Huang, MD, Professor of Peking University Institute of Hematology, Peking University People's hospital, No 11 Xizhimen South Street, Beijing 100044, China. Tel: +86 010 88326006; fax: +86 010 88324577; e-mail: firstname.lastname@example.org © 2012 Lippincott Williams & Wilkins, Inc.